Blood

Vol. 147, Issue 15 Issue 15 2026
19
Articles

Articles in this Issue

Das not enough in CBF AML

Richard M. Stone Apr 09, 2026 pp. 1658-1659 10.1182/blood.2025032734

Clonal hematopoiesis and lymphoma-associated mutations in hematopoietic progenitors in B-cell non-Hodgkin lymphoma

Laura Wiegand, Patricia Silva, Daniel Noerenberg et al. Apr 09, 2026 pp. 1723-1734 10.1182/blood.2025030489

Abstract The contribution of clonal hematopoiesis (CH) and disease-initiating precursors in B-cell non-Hodgkin lymphomas (B-NHLs) remains underexplored. Such precursors may drive c...

Digging deep for the roots of lymphoma

Joseph G. Schroers-Martin Apr 09, 2026 pp. 1657-1658 10.1182/blood.2025032718

Targeted therapy in early-stage classical Hodgkin lymphoma

Tomohiro Aoki, John Kuruvilla Apr 09, 2026 pp. 1655-1657 10.1182/blood.2025032560

Rescue gone rogue: the ERCC6L2 syndrome and TP53 mutations

Timothy Chlon Apr 09, 2026 pp. 1651-1652 10.1182/blood.2025032796

Li S, Pal R, Monaghan SA, et al. IMiD immunomodulatory compounds block C/EBPβ translation through eIF4E down-regulation resulting in inhibition of MM. <i>Blood</i> . 2011;117(19):5157-5165.

Apr 09, 2026 pp. 1781-1781 10.1182/blood.2026033419

Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease

Roman R. Schimmer, Nancy Klemm, Jonas Fullin et al. Apr 09, 2026 pp. 1663-1679 10.1182/blood.2025030230

Abstract Recessively inherited loss-of-function mutations in excision repair cross-complementing 6–like 2 (ERCC6L2) cause a bone marrow failure (BMF) syndrome characterized by mode...

A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia

Hartmut Döhner, Daniela Späth, Maral Saadati et al. Apr 09, 2026 pp. 1735-1748 10.1182/blood.2025030722

Abstract Core-binding factor acute myeloid leukemia (CBF-AML) is associated with KIT mutations and deregulated expression of KIT. We report results from the randomized, open-label,...

Ibrutinib: 10 years and counting

Jennifer R. Brown Apr 09, 2026 pp. 1653-1654 10.1182/blood.2025032468

Ring of fire cells: plasma cell–predominant relapse of Waldenström macroglobulinemia

Pedro Perez, Alex Freire Sandes Apr 09, 2026 pp. 1779-1779 10.1182/blood.2025031678

Charting human developmental hematopoiesis in vitro to open new routes for regenerative medicine

Claudia Castiglioni, Riccardo Piussi, Andrea Ditadi Apr 09, 2026 pp. 1680-1692 10.1182/blood.2024028063

Abstract The hematopoietic system performs essential functions for living organisms through a wide array of cell types, including immune cells for host defense, erythrocytes for ox...

CML mimicker: a myeloid neoplasm with <i>BCR</i> :: <i>FGFR1</i> fusion without peripheral blood eosinophilia or basophilia

Huan-You Wang, James K. Mangan Apr 09, 2026 pp. 1780-1780 10.1182/blood.2025032576

Heating up coagulation through necroptosis

Bernd Engelmann Apr 09, 2026 pp. 1659-1660 10.1182/blood.2025032672

GVHD fails the acid test

Ronjon Chakraverty Apr 09, 2026 pp. 1660-1662 10.1182/blood.2025032810

Gastrin for the treatment of acute graft-versus-host disease of the stomach

Jana Gawron, Marie Czech, Tamina Rückert et al. Apr 09, 2026 pp. 1763-1778 10.1182/blood.2025031080

Abstract Acute graft-versus-host disease (aGVHD) is a major cause of death after allogeneic hematopoietic cell transplantation, and patients with steroid-refractory aGVHD have a di...

How I approach clinical ethics consultation in hematology

Jonathan M. Marron, Lindsay R. Semler, Gregory A. Abel Apr 09, 2026 pp. 1693-1701 10.1182/blood.2025029985

Abstract Caring for individuals with hematologic disorders is increasingly complex, and with medical complexity often comes ethical complexity. Prognostic uncertainty, stakeholder...

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma

Jeremy S. Abramson, David J. Straus, Nancy L. Bartlett et al. Apr 09, 2026 pp. 1713-1722 10.1182/blood.2025030190

Abstract Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, al...

A decade of ibrutinib for CLL with and without <i>TP53</i> aberration: final report on an investigator-sponsored phase 2 study

Andy Itsara, Victoria M. Rogness, Laura Samples et al. Apr 09, 2026 pp. 1702-1712 10.1182/blood.2025029971

Abstract Bruton tyrosine kinase inhibitors improve outcomes for patients with chronic lymphocytic leukemia (CLL). Long-term data with continuous therapy are limited. With a median...

Heat stress activates the coagulation cascade through Z-DNA-binding protein 1–dependent necroptosis

Fanglin Li, Jinxiu Li, Jian Shi et al. Apr 09, 2026 pp. 1749-1762 10.1182/blood.2025030764

Abstract Heatstroke, a severe hyperthermic condition, is characterized by a core body temperature &amp;gt;40°C and multiple organ dysfunction syndrome (MODS), with an extremely hig...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page